| __timestamp | Amicus Therapeutics, Inc. | BioMarin Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 20717000 | 302156000 |
| Thursday, January 1, 2015 | 47269000 | 402271000 |
| Friday, January 1, 2016 | 71151000 | 476593000 |
| Sunday, January 1, 2017 | 88671000 | 554336000 |
| Monday, January 1, 2018 | 127200000 | 604353000 |
| Tuesday, January 1, 2019 | 169861000 | 680924000 |
| Wednesday, January 1, 2020 | 156407000 | 737669000 |
| Friday, January 1, 2021 | 192710000 | 759375000 |
| Saturday, January 1, 2022 | 213041000 | 854009000 |
| Sunday, January 1, 2023 | 275270000 | 937300000 |
| Monday, January 1, 2024 | 1009025000 |
Data in motion
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for sustaining growth and innovation. Over the past decade, BioMarin Pharmaceutical Inc. and Amicus Therapeutics, Inc. have shown distinct trends in their SG&A expenditures.
From 2014 to 2023, BioMarin's SG&A expenses surged by over 200%, peaking at nearly 937% of their 2014 levels. This reflects their aggressive expansion and investment in administrative capabilities. In contrast, Amicus Therapeutics, while also increasing their SG&A expenses, did so at a more moderate pace, growing by approximately 1,230% over the same period.
These trends highlight the strategic differences between the two companies. BioMarin's larger scale and broader market reach necessitate higher administrative costs, while Amicus's more focused approach allows for leaner operations. Understanding these dynamics offers valuable insights into the operational strategies of leading biotech firms.
Johnson & Johnson or Amicus Therapeutics, Inc.: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Pfizer Inc. and Amicus Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Sanofi and Amicus Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Summit Therapeutics Inc. and BioMarin Pharmaceutical Inc.
Comparing SG&A Expenses: Insmed Incorporated vs BioMarin Pharmaceutical Inc. Trends and Insights
Who Optimizes SG&A Costs Better? BioMarin Pharmaceutical Inc. or Madrigal Pharmaceuticals, Inc.
BioMarin Pharmaceutical Inc. and Travere Therapeutics, Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: BioMarin Pharmaceutical Inc. vs Xencor, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Opthea Limited and Amicus Therapeutics, Inc.
Comparing SG&A Expenses: Veracyte, Inc. vs Amicus Therapeutics, Inc. Trends and Insights
ACADIA Pharmaceuticals Inc. and Amicus Therapeutics, Inc.: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Amicus Therapeutics, Inc. and Galapagos NV